The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections.

The present invention provides compositions and methods for inducing DNA breaks in specifically-targeted cells, in particular cancer and HIV-infected cells, thereby promoting cell death.

Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

There is provided a retroviral RNA vector comprising a 5 cap, a transgene, a 3 long terminal repeat (LTR) and an RNA packaging sequence, wherein translation of the transgene is initiated at the 5 end of the transgene in a cap-dependent manner, and wherein the 3 LTR and the RNA packaging sequence are located 3 of the transgene. Also provided is a nucleotide sequence encoding a vector genome. In addition, there is provided a host cell, a virion and a pharmaceutical composition comprising the vector or nucleotide sequence, and the use of the vector in delivering a transgene to a cell or subject.